Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised…

Overview of attention for article published in Frontiers in Pharmacology, February 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 6,722 followers.

RT @Dr_Kevin_Pruitt: Check out our collaborative work in @FrontPharmacol by @IsaCast03614613, @ttuhscmed, @TTUHSC_GSBS. We investigate the…

14 Mar 2022

Reply Repost Favourite

Check out our collaborative work in @FrontPharmacol by @IsaCast03614613, @ttuhscmed, @TTUHSC_GSBS. We investigate the impact of chronic administration of Cannabinoid Receptor 2 Agonists on tumor growth and endocannabinoid levels using in vivo models. 🔎 h

14 Mar 2022

Reply Repost Favourite

New Research: Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice https://t.co/UAyi3Gvk9N #phar

15 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.